首页> 外文期刊>Biochemistry >Receptor-Mediated Transfer of DNA-Galactosylated Poly-L-lysine Complexes into Mammalian Cells in vitro and in vivo
【24h】

Receptor-Mediated Transfer of DNA-Galactosylated Poly-L-lysine Complexes into Mammalian Cells in vitro and in vivo

机译:受体介导的DNA-半乳糖基化聚-L-赖氨酸复合物在体外和体内转移到哺乳动物细胞中

获取原文
获取原文并翻译 | 示例
           

摘要

With the goal of developing non-viml techniques for exogenous gene delivery into mammalian cells, we have stud- ied receptor-mediated gene transfer using complexes of plasmid DNA and galactosylated poly-L-lysine, poly(L-Lys)Gal. To evaluate the optimal parameters for efficient gene transfer into human hepatoma HepG2 cells by the DNA-poly(L-Lys)Gal complexes, the bacterial reporter genes lacZ and cat were used. Examination of the reporter gene expression level showed that the efficiency of DNA delivery into the cells depends on the structure of DNA-poly(L-Lys)Gal complexes formed at various ionic strength values. The efficiency ofDNA transfer into the cells also depends on DNA/poly(L-Lys)Gal molar ratio in the complexes. Plasmid vector carrying human apolipoprotein A-I (apoA-I) gene was injected as its complex with poly(L-Lys)Gal into rat tail vein. Some level of ApoA-I was detected in the serum of the injected rats. Also, the human apoA-I-containing plasmid was found to be captured specifically by the rat liver cells and transported into the cell nuclei, where it can persist as an episome-like structure for at least a week. After repeated injections of DNA-poly(L-Lys)Gal com-plexes, the level of human ApoA-I in rat serum increases, probably, due to accumulation of functional human apoA-I gene in the liver cell nuclei. The data seem to be useful for the development of non-viml approaches to gene therapy of cardio-vascular diseases.
机译:为了开发将外源基因传递到哺乳动物细胞的非viml技术,我们已经使用质粒DNA和半乳糖基化的聚L-赖氨酸,聚L-LysGal复合物研究了受体介导的基因转移。为了评估通过DNA-poly(L-Lys)Gal复合物有效地将基因导入人肝癌HepG2细胞的最佳参数,使用了细菌报告基因lacZ和cat。检查报告基因的表达水平表明,DNA进入细胞的效率取决于在各种离子强度值下形成的DNA-poly(L-Lys)Gal复合物的结构。 DNA转移到细胞中的效率还取决于复合物中DNA / poly(L-Lys)Gal摩尔比。将携带人载脂蛋白A-1(apoA-I)基因的质粒载体与poly(L-Lys)Gal的复合物注入大鼠尾静脉。在注射的大鼠的血清中检测到一定水平的ApoA-I。而且,发现含有人apoA-I的质粒被大鼠肝细胞特异性捕获并转运到细胞核中,在那里它可以作为附加体状结构持续至少一周。重复注射DNA-poly(L-Lys)Gal复合物后,大鼠血清中人ApoA-I的水平可能增加,这可能是由于功能性人apoA-I基因在肝细胞核中的积累。该数据似乎对于开发用于心血管疾病的基因疗法的非viml方法很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号